Insulin-like growth factor (IGF) binding protein -3 (lGFBP-3) regulates cell proliferation and survival by extracellular interaction and inactivation of the growth factor IGF-1. Beyond that, IGF-independent actions mediated by intracellular IGFBP-3 including nuclear-IGFBP-3, have also been described. We here show, using both confocal and electron microscopy and cell fractionation, that the extracellular addition of IGFBP-3 to living cells results in rapid uptake and nuclear delivery of IGFBP-3, by yet partly unknown mechanisms. IGFBP-3 is internalized through a dynamin-dependent pathway, traffics through endocytic compartments and is finally delivered into the nucleus. We observed docking of IGFBP-3 containing structures to the nuclear envelope and found IGFBP-3 containing dot-like structures to permeate the nuclear envelope. In summary, our findings establish the pathway by which this tumor suppressor protein is delivered from extracellular space to the nucleus.
IGFBP-3 also induced apoptosis in human osteosarcoma cells, and apoptosis induction was limited by ubiquitination of IGFBP-3 followed by its proteasomal degradation.
lo Of note, IGFBP-3 was suggested as tumor suppressor in the prostate, II and subsequently recombinant IGFBP-3 was shown to induce apoptosis in prostate cancer cells,7,12 as well as in a transgenic mouse model of prostate canceL I 3 In addition to IGF-related fu nctions of IGFBP-3, IGFindependent actions of IGFBP-3 contribute to its antiproliferative and proapoptotic activities. 14 Thus, IGFBP-3 can induce programmed cell death in IGF-IR-negative mouse fibroblasts 7 ; furthermore, IGFBP-3 mutants that do not bind IGFs can stimulate apoptosis in cancer cells 10,12 and inhibit prostate tumor progression in a transgenic mouse model,13 suggesting a nuclear function of IGFBP -3, probably related to transcriptional regulation. Indeed, IGFBP -3 contains a nuclear loca lization sequence (NLS) in its conserved C-terminal domain 15 and nuclear localization of IGFBP-3 has been reported in human cancer cells. 16 Accordingly, IGFBP-3 can interact with nuclear transcription factors, such as the retinoid X receptor. 17 Importantly, the extracellular addition of recombinant human induces cell death in cultmed prostate cancer cells (see above), and the in fusion of recombinant IGFBP -3 has been successfully used as an experimental tllerapeutics in a mouse model for prostate cancer. 13 Based on iliese results, iliere are attempts to develop ilierapies for human prostate cancer based on rhIGFBP-3. 18 In view of the potential of rhIGFBP-3 as anticancer drug, it is essential to understand the mechanisms by which extracellular IGFBP-3 acts on tumor cells, and if nuclear functions of IGFBP-3 are relevant for such action. In several cell types, IGFBP-3 can be internalized by endocytosis, 19.20 but ilie precise mechanisms underlying the cellular uptake of IGFBP-3 are currently not known. In addition, importin-beta-dependent nuclear import of cytosolic IGFBP-3 into tile nucleus has been demonstrated in permeabilized Chinese hamster ovary cells,I 5 but it is currently unclear wheilier tile same mechanism mediates nuclear uptake of IGFBP-3 in intact cells. We here investigated the dynamics of cellular uptake of IGFBP-3 and its transport to the nucleus by live cell imaging, electron microscopy and biochemical fractionation in human osteosarcoma cells and observed rapid nuclear delivelY of IGFBP-3 subsequent to its endocytic uptake.
Material and Methods

Chemicals
All chemicals were purchased from Sigma (Vienna, Austria) unless indicated otherwise.
Cell cu ltu re U-20S human osteosa rcoma cell s were obtained from ATCC (American Type Culture Collection, Wesel, Germany) and were maintained in DMEM (Sigma, Vienna, Austria), supplemented with 10% FCS (Biochrom, Berlin, Germany), 2 mM L-glutamine and 100 U/mL penicillin with 0.1 mg/mL streptomycin (Gibco, Invitrogen, Lofer, Austria) . The cells were grown in an atmosphere of 5% CO 2 at 37°C and were subcultured by tlypsinization with 0.05% trypsin-EDTA (Gibco, Invitrogen, Lofer, Austria) eve ry 3-4 days.
Purification and labeling of human IGFBP-3
Native human IGFBP -3 was produced in U-20S cells transfected wiili an IGFBP-3 expression vector, and ili e protein was isolated from the conditioned supernatant, as described previo usly.21 A purification control was perform ed by subjectin g supern atant of mock-transfected U-20S to ilie same purification procedure as unlabeled IGFBP -3. IGFBP -3 concentration was determined usin g a sandwich ELISA (R&D Systems, Abingdon, UK). Purified IGFBP-3 was labeled with Al exa Fluor, nanogold and HRP by commercially available kits. A detail ed description of labeling procedures is provided in th e Supporting Informatio n. 1545 
Plasm Ids and transfection
The mCherry cDNA was kindly provided by Dr. Roger Tsien (Stanford, CA, USA). The mCherry-NLS containing three copies of the SV40 LT NLS was cloned using routine cloning procedures. pEF-NLS -GFP vector was a kind gift from Dr. Stephan Geley (Innsbruck, Austria). pNup1 53-EGFP plasmid was kindly provided by Dr. Jan Ellenberg (Heidelberg, Germany). Constructs coding for dyn am in 2 GFP wild type (WT) and dominant negative K44A 22 were both kindly provided by Dr. Mark McNiven (Rochester, MN, USA). The Rab-7 mCherry construct was kindly provided by Dr. Natalia Schiefermeier (lnnsbruck, Austria). U -20S cells we re plated at a density of 5 x 10 4 ce lls per well in the 8-well Lab-Tek Chamber Slide System (Nalge Nunc International, Naperville, IL, USA), 6 hI' prior to transfection. Cells were tranSiently transfected with Lipofectamine 2000 (Invitrogen, Lofer, Austr ia) acco rding the manufacturer's protocol using 0.3 ~lg of plasm id DNA. On the next day, medium was replaced and experiments were performed within the next 12 hr.
Endocytosis assays and live cell confocal microscopy
For uptake experiments of fluorescence-labeled IGFBP-3, U -20S cells were plated at a density of 5 x 10< 1 cells per well in the 8-well Lab -Tek Chamber (Nalge Nunc International, Napervill e, IL, USA), 24 hI' before the experiments were started. Ten ~lg/mL of Al exaFluor647-labeled IG FBP-3 was added to the cells at the same time as endocytic model substrates. The following concentrations were used: 15 ~lg/mL Transferrin AlexaFluor568 (Invitrogen, Lofer, Austria), 10 Ilg/mL Cholera Toxin Subunit B AlexaFluor488 (Molecular Probes, Invitrogen, Lofer, Austria), and 3 mg/mL Dextran AlexaFluor488 (Molecular probes, Invitrogen, Lofer, Austria). For colocalization studies of IGFBP -3 with a marker for acidic vesicles, 75 nM Lysotracker Red DND-99 (LTR; Invitrogen, Lofer, Austria) was used. Cells were coincubated either wiili IGFBP-3 AlexaFluor647 and LTR for up to 2 hr or preincubated wiili IGFBP-3 for 2 hr and LTR was added to the cells for addition al 5 or 30 min. For nuclear staining, 3 ~lM Syto l6 Green-Fluorescent Nucleic Acid Stain for living cells (Molecular probes, Invitrogen, Lofer, Austria) was used. For 3-D reco nstruction of IGFBP-3 nuclear uptake, 10 ~lg/mL AlexaFluor568-and/or 647-labeled IGFBP -3 was used. Incubation and confocal imagi ng analysis of U-20S cells was performed in the 8-well Lab-Tek Chamber (Nalge NW1C International, Naperville, IL, USA). Live cell imaging was performed with a Nipkow disk-based confocal system U ltraVIEW RS (Perkin Elmer, Welles ley, MA, USA) and the LSM510META on an Axiovert200 stand equipped with a temperature controlled incubation chamber (Pecon, Erbach, Germ any) . A detailed description of imaging procedures is provided in the Supporting Information.
Electron microscopy
For uptake experiments of IGFBP-3 conjugated with nanogold or HRP, U-20S cells we re plated at the denSity of 7. 
OIGFBP3
.M~rk.r cove rsli ps2J Uptake was initiated by the additio n of 10 ~lgl mL nanogold or HRP labeled IGFBP-3 to th e m ed ium . As a negative con trol, nonco njugated nanogold (Nanoprobes, Yaphank, NY, USA) or HRP (Sigma, Vienna, Austria) was used. After 2-4 h r incubation, cells were processed for electron microscopy. Co nvent ional chemical fIxation ( glutaraldehyde in 0.1 M phosphate buffer, pH 7.4, 120 min, RT) yielded unsatisfactory preservation of cytoplasmic organelles in preliminary experiments. Therefore, cryo-based specimen fixation (high -pressure freezing) was employed. Subsequently, samples were subj ected to freeze -substitution (with acetone containing 0.5% (v/v) glu taraldehyde, optionally supplemented with 0.2% (w/v) uranyl acetate and 4% (v/v) water) and sample rehydration 2 ".25 Samples were rinsed with double distilled water and subjected to silver enhancementwhen appropriate-(HQ-S ilver (Nanoprobes, Yaphank, NY, USA), 7-9 min, RT) of the 1.4 nm-small nanogold particles. 26 T his enhancement procedure produced in our case particles of ~35 nm with almost no unspecific background. IGFBP-3-HRP was visualized by means of DAB-cytochemistry.z~ After short postiL-xation with aqueous OSO' 1 (I % w/v), samp les were embedded in epoxy resin and serial th in sections were viewed with a Philips CM 120 transmission electron microscope that was equipped with a goniometer stage.
Cell fractionation and immunoblotting
For uptake of unlabeled IGFBP-3 protein, U -20S cells were seeded in a cul ture dish to reach a density of 80% at th e day of the experiment. Cells were incubated with 15 ~lg of rhIGFBP -3 in serum-free DMEM for 2 hr. Supernatants from mo ck-transfected U-20S cells, purified in the same way as IGFBP -3 supernatants, were used as control. For fra ctionation experiments, U-20S cell s were cultured in 75 cm 2 flasks.
The cells were harvested in 0.05% trypsin -EDTA (Gibco, Invitrogen, Lofer, Austria). Cells were washed four-times with cold PBS and fractionated into th ree different cellular compartments (cytosol, membranes and nucleus) by Qproteome Cell Compartment Kit (Qiagen, V ien na, Austria), accord in g th e manufacturer's instructions. Purity of individual fract ions was verifi ed by Western blot ana lysis usi ng antibodies agai nst specific markers for each fract ion, as described. 'o The following antibodies were used for Western blot ana lysis: goat polyclonal antibody to IGFBP-3 (R&D Systems, Abingdon, UK); mouse monoclonal antibody to nuclear matrix protein p84 (Abeam, Cambridge, UK); mouse monoclonal antibody to ATP-synthase subunit alpha (ATP5A l; Molecular probes, Invitrogen, Lofer, Austria); goat antipyruvate kinase (rabbit muscle) antibody (M2PK; Rockland, Gilbertsvill e, PA, USA). For a quantitative assessment of IGFBP-3 uptake, IGFBP -3 protein gels were run exceptionally shorttime to allow all IGFBP-3 isoforms to be quantified as a single band.
Results
To evaluate the biological act ivity of recombin ant native IGFBP-3, the protein was added to U-20S osteosarcoma cell s, wh ich were then monitored over a total of 2 cell cycles (ca ., 32 hr). Under these conditions, we observed a moderate but significa nt increase in the number of apop totic cells In th e lower panels, contours of both transfected an d untransfec ted cells were drawn for th eir better vi sua liza tion .
(b) Ce lls were co-transfe cted with exp ress ion vecto rs coding dynamin 2 GFP WT or ON K44A (blu e fluoresce nce) and for nuclear fluoresce nt protein mCherry (here: gree n fluo rescence), as in dicated. 24 hr after transfection, IGFBP-3 AlexaFluor647 (red fluorescence) was added an d ce lls were monitored by co nfo ca l live ce ll mic rosc opy for 2 hr. mCherry nuclear fluoresce nc e was used as a marker for the auto fo cus and track in g macro . Images of two representative cells obta ined at th e indicated time points are shown . Bar, 10 ~lm. (Supporting Information Fig. S1 ) along with a reduced number of mitotic cells (Supporting Information Fig. SI) , consistent with previous studies,4. lo suggesting that U -2 0S cells are a suitable model system to study IGFBP-3 uptake. Subsequently, recombinant native IGFBP-3 was labeled with two distinct fluorescent dyes, AlexaFluor568 and 647, and used for live cell imaging. IGFBP -3 was efficiently labeled with both dyes (Supporting Information Fig. S2 ) and retained biological functions, e.g., to sequester I GF-I and thereby suppress AKT signali ng27 (Supporting Information Fig. S3 ). U-20S cells were then coincubated with fluorescent IGFBP-3 and fluorescent model cargoes for clathrin-mediated endocytosis, caveolar endocytosis and fluid -phase endocytosis, respectively.
When IGFBP-3 was added along with transferrin (T£), Tfpositive vesicular structures were readily observed after 20 min, whereas the uptake of IGFBP-3 was much slower. We found that at ea rly time points the vast majority of Tf-positive vesicles were negative for IGFBP-3, and only a minor proportion of IGFBP-3 containing vesicles were also positive for Tf (Fig. 1a) . Two hours after the addition of both sub- Whereas in each experiment only those vesicles were visible (and therefore counted) that were positive for either IGFBP-3, the control cargo, or both, the density of IGFBP-3 positive vesicles per cell was similar in all uptake experiments (Supporting Information Fig. S4 ). These data indicate that all three uptake routes studied h ere contribute to tl1e net up take of IGFBP-3. This point was further addressed by RNA interference targeting specific components of endocytic pathways, i.e., clathrin heavy chain 29 for the clathrin coated pit pathway, caveolin 1 J O for caveolar endocytosis and PAlO for fluid -phase endocytosis. 3 1 We found that knocking down either clathrin heavy chain or caveolin I, both reduced the internalization of IGFBP-3, suggesting that IGFBP -3 uptake indeed utilizes both clathrin-mediated and caveolin-mediated endocytosis (Figs. la, 1b, and If) . After knocking down PAK1, IGFBP-3 uptake was reduced at an early time point (20 min), whereas at later time points the effect was no longer visible. These findings suggest that fluid-phase endocytosis mainly contributes to early steps of IGFBP-3 uptake (Figs. Ie and If) .
To address the relationship between IGFBP-3 containing vesicles and endosomes/lysosomes, acidic vesicles (i.e., mainly lysosomes) were labeled with Lysotracker Red ONO-99 (LTR) . Twenty minutes after the addition of IG FBP-3 and L TR, 65 ± II % of IGFBP-3 containing vesicles also contained LTR and this ratio increased to 86 ± 1.6% after 2 hI' (Figs. 1d and Ie). The number of LTR positive vesicles containing also IGFBP -3, increased from 6% (20 min) to 36% (2 hr). The predominant presence of intracellular IGFBP-3 in endosomesllysosomes was confirmed in a second set of experiments, where LTR was added to th e cells 2 hr after adding IGFBP-3. Shortly after addition of LTR, nea rly all IGFBP-3 containing vesicles showed LTR fluorescence (Figure 55) . T he data suggest that IGFBP-3 is mainly contained in endosomesllysosomes after in ternalization.
AlexaFluor568 a b c
Most if not all endocytic processes depend on dynamin, which is required for vesicle movements.
32 To address the role of dyn amin in IGFBP -3 uptake, we expressed GFP fusion proteins either of WT dynamin 2 or its dominant negative mutant (K44A), which is unable to support endocytic AlexaFluor647 Figure 5 .
uptake of extracell ular substrates.
22
, In both experiments, untransfected (GFP negative) cells served as internal controls. IGFBP-3 was added to transfected cells and its uptake was studied by live cell imaging. Within 30 min, cells expressing WT dynamin 2 readily internalized IGFBP-3, in contrast to cells expressing the K44A mutant (Fig. 2a) . We, furthermore, monitored uptake of IGFBP-3 for 2 hr by confocal microscopy. We observed time-dependent accumulation of IGFBP-3 in cells overexpressing WT dynamin 2, whereas this process was impaired in cells expressing dominant negative dynamin 2 (Fig. 2b, Supporting Information Fig. S6 ), confirming that dynamin 2 function is essential for uptake of extracellular IGFBP-3.
To study nuclear uptake of IGFBP-3, its subcellular localization was monitored by time lapse confocal microscopy over 2 hr using U-20S cells expressing NLSmCherry.3.1 With increasing incubation time, we observed the accumulation of IGFBP-3 containing vesicles in the cytoplasm. At later time points, IGFBP-3 containing vesicles were found in close association with the nucleus (Fig. 3a) , and rarely, a few discrete IGFBP-3 containing dot-like structures were detected inside the nucleus (Fig. 3b) , along with an increase in overall IGFBP-3 nuclear staining (Supporting Information Fig. S7) . A similar increase in nuclear IGFBP-3 was observed in cells expressing WT dynamin 2 but not in cells expressing the mutant K44A (Supporting Information Fig. S8) .
To define the outline of the cell nucleus, nucl eopori n 153-GFP fusion protein (NupI53-GFP),3' 1 was expressed in U-20S cells before fluorescent IGFBP-3 was added. After 2 hr, IGFBP-3 was clearly present within the nucleus (Fig. 3c) and dynamic interaction of IGFBP-3 containing vesicles with the nuclear envelope and the eventual transfer of IGFBP-3 containing dot -like structures into the nucleoplasm (Fig. 3d , Supporting Information, Vide03D.mov) was observed. Nuclear delivery of IGFBP-3 was also analyzed using the nuclear counterstain Syto l 6, added a few seconds before time lapse confocal microscopy was started (Fig. S9) . In this experiment,
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we observed fast translocation of IGFBP -3 into the nucleus (Supporting Information, VideoS9.mov). The rapid disappearance of nuclear IGFBP-3 containing structures observed here may be due to rapid diffusion; it may be further enhanced by the fact that nuclear IGFBP -3 is subj ect to ubiquitin/proteasome-dependent proteolysis.
l o
To study the uptake and intracellular distribution of extracellularly administrated IGFBP-3 by cryo-based electron microscopy, IGFBP-3 was covalently linked to nanogold particles or HRP (Fig. S2) . Two to 4 hr after addition to the cells, IGFBP-3 labeled by either method was localized both within endocytic vesicles and inside the nucleus of morphologically intact cells (Figs. 4a, 4b, and 4c) . As in fluorescence microscopy, IGFBP-3 containing vesicles were found in close contact with the nuclear envelope (Fig. 4d) . Unconjugated nanogold particles or HRP were used as controls, which yielded virtually no intracellular nanogold particles or intranuclear HRP-DAB-reaction product, respectively (data not shown) .
To further explore nuclear delivery of exogenously added IGFBP-3, we acquired high resolution 4D reconstructions using confocal live cell microscopy followed by deconvolution. The obtained images confirmed the presence of IGFBP-3 containing dot-like structures in the nucleus several hours after addition of IGFBP-3 to the cells (Supporting Information Fig. SID ; see Supporting Information Fig. SI1 for raw data without deconvolution). The restored images clearly revealed highly dynamic intranuclear IGFBP-3 containing structures ( Fig. Sa; see Figure S12 for the exact cutting position). To further address the pathway underlying IGFBP-3 nuclear import, we used mCherry-tagged Rab -7 as a specific marker for late endosomes (Fig. 5b) . These experiments confirmed that IGFBP-3 is present in late endosomes only prior to nuclear uptake and demonstrated that IGFBP-3 in the nucleus was not associated with A 3D analysis of ultrastructural data was also performed. Using EM serial sections, we found IGFBP-3-nanogold clusters in the nucleus which were entirely located in the Figure 5 . Tim e resolved 3D reconstruction of lGFBp·3 nuclear uptake. (a) Time course 3D reconstructions. U-2 0S cells were transfected with Nup153-GFP (green fluorescence) and incubated for 3 hr with IGFBP-3 (red fluorescence) labe led by either AlexaFluor568 or AlexaFluor647 as indi cated. Data were recorded by confocal laser scann in g microscopy (5P5, left panel) and confocal sp innin g disc microscopy (SO, ri ght panel). 3D stacks were acquired continuously over time, deconvolved and processed by Im aris software as described in Material and Methods. 3D reconstruction s were made of Nup153 and lGFBP-3 positive structures, showing the nuclea r interior (perspective sca le; grid major tick, 2 rim). The isosurface rendered to Nup153-GFP, corresponding to the inn er and outer borders of the nuclea r enve lop e, is shown in cyan . Note the iso lated red lGFBP-3 containing structures in th e nucleus indicated by arrows (see Supportin g Information Fi g. 510 for orthogonal sections after deconvolution, 511 for raw data without deconvolution and Supportin g Information Fig. 512 for the exact cutting positions). (b) 3D reconstructions of U-20S ce lls transfected with Nu p153-G FP (blue fluoresce nc e), Rab-7 mCheny (green fluorescence) 3 hr after the incub ation with lGFBP-3 AlexaFluor647 (red fluorescence) are shown (nuclear interior: perspective scale; grid major tick, 2 rim). Th e isosurface rendered to Nup15 3, corresponding to the inn er and outer borders of the nuclear envelope, is shown in grey. Note the isolated red IGFBp·3 containing structu res in the nucleus (arrow), and IGFBP-3 colocalized with Rab-7 in th e cytoplasm and in close contact with the nucl eus (arrow head). (e) Three-dimensional EM -ana lysis of the nuclear localization of exogenously added lGFBP-3 : A series of consec utive 100 nm -thin sections through the area fram ed in the overview clearly revea led a cluster of nuclear IGFBP-3-nanogold (arrow- nucleoplasm with no connection to the cytoplasm (Fig. Sc) , clea rly showing that extracellular IGFBP-3 was delivered into th e nucleus. To further explore th e n uclear uptake of IG FBP -3 from the extracellular space usin g a biochemical assay, unlabeled IGFBP-3 was added to U-20 S cells, which contain low levels of endogenous IGFBP-3, I 0 foll owed by cell fra ctionation. To determine the distrib ution of IGFB P-3 between di fferent cellul ar subfractions, equal aliquots of each fraction (3%) were loaded on SDS-PAGE and analyzed by Wes tern blot using IGFBP-3 antibodies. Two hours after addition to U-20S cells, IGFBP-3 was detected in the nuclear fraction by Western blot (Fig. 6a) . This observation may reflect IGFBP -3-containing vesicles that are tightly assoc ia ted with the nucleus and/ or IGFBP-3 molecu les inside the nucleus. All major IGFBP-3 bands could be retrieved from the nuclear fraction, when compared with the input IGFBP-3 preparation (Fig. 6b) . Apparently, intact IGFBP-3 reaches the nuclear fraction, suggesting that if IGFBP-3 is degraded in the acidic vesicles, this process is quite inefficient.
Because importin -beta is the main import factor required for nuclear import of cargo from the cytosol,35 we addressed its role in nuclear import of IGFBP-3. When importin-beta was depleted by specific siRNA (Fig. 6c) , we observed a reduction of nuclear nucleophosmin, a well -known cargo of the importin -dependent nuclear import pathway.36 Depletion of importin-beta also led to a significant reduction in the abundance of nuclear IGFBP-3 to 29 :!:: 9.5% (Fig. 6c) . This observation suggests that the classical nuclear import pathway contributes at least partially to nuclear uptake of internalized IGFBP-3. However, the general rate of IGFBP-3 uptake was also reduced in U-20S cells, upon impo rtin -beta depletion (Fig. 6d) , rendering further conclusions about the role of importin-beta in the nuclear import of IGFBP-3 rather difficult.
Discussion
We here provide detailed information about the uptake route of rhIGFBP-3 in living human cancer cells. The key observation described in this report is that the addition of recombinant human IGFBP-3 to living human osteosarcoma cells results in the rapid (2 hr) appearance of IGFBP -3 in the nucleus. This finding is backed up by time lapse confocal microscopy of IGFBP-3 endocytosis, by electron microscopy, and by cell fractionat ion experiments.
IGFBP-3 endocytosis
Endocytic uptake of IGF binding proteins, such as IGFBP-3 19 . 20 and IGFBP _5 19 ,J7 was described before. Concerning IGFBP-5, the mechanisms of cellular and nuclear delivery have been discussed controversially,3R and one recent study came to the conclusion that nuclear uptake of extracellular IGFBP-5 does not occur in intact cells but requires the prior permeabilization of the cellular membranes 37 In our study, we demonstrate nuclear uptake of extracellular IGFBP-3 in intact living cells, and our results provide new info rmation on this process. As the model substrates Tf, CT and Dex all partly colocali zed with IGFBP-3 during endocytosis, we conclude that IGFBP-3 uses the three major endocytic pathways, i.e. , the caveolin dependent endocytic route, the clathrin coated pit endocytic pathway and the fluid -phase endocytic pathway.
Further evidence supporting multiple uptake mechanisms came from experiments with siRNA-mediated gene silencing. Thus, knock down of caveolin I and dathrin heavy chain significantly reduced the number of IGFBP-3 containing ves icles. Consistent with a major involvement of endocytic pathways 1555 for IGFBP-3 uptake, dynamin 2, a common hub of the main endocytic pathways39 was absolutely required for uptake of IGFBP-3. Whereas TGF-beta receptor type V was described as a cell surface receptor for IGFBP-3,40 the membrane receptor(s) of IGFBP -3 required for the clathrin coated pit endocytic pathway remain to be identified. Whereas in principle receptor-independent fluid phase uptake co uld be sufficient for IGFBP -3 delivery across the plasma membrane, our data do not suggest a major role for fluid-phase endocytosis for IGFBP-3 uptake.
Nuclear localization of IGFBP-3
Based on immunofluorescence studies with fixed cells, others reported quite uniform nuclear localization of IGFBP-3 in IGFBP-3 secreting PC-3 prostate cancer cells. 20 In our study, we detected IGFBP-3 clusters as well as homogenously distributed IGFBP-3 throughout the nucleus both by LM and EM. Whereas we used one and the same recombinant IGFBP-3 for the different assays, the protein had to be differently labeled for each particular imaging application. However, we believe that the observed patterns reflect a genuine biological phenomenon and are not merely a consequence of using different labels, because distinct as well as diffuse intranuclear IGFBP-3 signals were independently observed by various LM and EM techniques. Thus, nuclear IGFBP -3 forms quite large, short-lived objects, which are devoid of the late endosomal marker Rab -7. One possible explanation for the observed bimodal distribution of nuclear IGFBP-3 is rapid diffusion of transient IGFBP-3 clusters after their entry into the nucleus. Because experiments with permeabilized cells suggested importin-dependent nuclear import of IGFBP _3,1 5 we explored the role of importin -beta in IGFBP-3 trafficking. Indeed, the depletion of importin-beta reduced the levels of nuclear IGFBP-3 (Fig. 6c) , indicating that the import in pathway contributes to nuclear delivery of IGFBP-3. However, importin-beta knock down also significantly reduced the total uptake of IGBFP-3 (Fig. 6d) , suggesting that the observed loss in nudear localisation may partly be due to a general reduction of IGFBP-3 endocytosis. Generally, the underlying mechanisms of nuclear delivery of extracellular proteins are poorly understood, but involvement of importin-beta in this process is likelyJ 5,.1 1 Recently, it was proposed that internalized EGF/EGFR complexes may leave endosomes at the nuclear-cytoplasmic interface and enter the nucleus via nuclear pores, implying the importin-beta complex. 42 Such a mechanism may also contribute to nuclear delivery of IGFBP-3, even though we have no direct evidence for such a scenario.
Nuclear functions of the insulin/IGFaxis?
There is evidence that IGFBP-3 can interact both phYSically and functionally with transcription factors, such as RXR.1 7 Thus, our finding that extracellular IGFBP-3 reaches the nucleus within 2-3 hI' (Figs. 3-6 ), raises the possibility that nuclear IGFBP-3 may trigger rapid transcriptional changes (in the receiving cell), due to its functional interaction with nuclear transcription factors. Consistent with this assumption, we found significant changes in the expression of several genes 6 hI' after addition of IGFBP-3 to human diploid fibroblasts (L. Micutkova, unpublished). However, more work will be required to elucidate the precise molecular mechanism(s) by which nuclear uptake of IGFBP-3 leads to changes in the expression of these genes. It is interesting to note that other components of the insulin/IGF Signaling pathway were described as targets for nuclear import. Thus, insulin receptor substrate-l (IRSI)"3 and insulin receptor substrate-2 44 translocate to the nucleus, and recent data suggest that the IGF receptor I can also translocate to the nucleus, in response to site specific sumoylation. 4s IRSI was also shown to interact with caveolin,46 resulting in mutual stabilization of both proteins.
47 extracellular IGFBP-3 is indeed translocated to the cell nucleus following well -described endocytic pathways, whereas the observed nuclear import mechanisms have to be further elucidated. Our findings provide a basis for iden tifying new regulators (e.g., IGFBP-3 receptors, or endosomal proteins) of IGFBP-3 uptake and nuclear delivery, aiming to better understand the ability of extracellular IGFBP-3 to suppress tumor progression in epithelial cancers.
